CN110551817A - Kit for detecting human WT1 fusion gene and use method thereof - Google Patents
Kit for detecting human WT1 fusion gene and use method thereof Download PDFInfo
- Publication number
- CN110551817A CN110551817A CN201810549583.1A CN201810549583A CN110551817A CN 110551817 A CN110551817 A CN 110551817A CN 201810549583 A CN201810549583 A CN 201810549583A CN 110551817 A CN110551817 A CN 110551817A
- Authority
- CN
- China
- Prior art keywords
- enzyme
- seq
- probe
- kit
- detecting
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 108090000623 proteins and genes Proteins 0.000 title claims abstract description 51
- 230000004927 fusion Effects 0.000 title claims abstract description 25
- 101000621309 Homo sapiens Wilms tumor protein Proteins 0.000 title claims abstract description 12
- 102000046004 human WT1 Human genes 0.000 title claims abstract description 12
- 238000000034 method Methods 0.000 title claims description 24
- 108090000790 Enzymes Proteins 0.000 claims abstract description 73
- 102000004190 Enzymes Human genes 0.000 claims abstract description 73
- 210000005259 peripheral blood Anatomy 0.000 claims abstract description 10
- 239000011886 peripheral blood Substances 0.000 claims abstract description 10
- 239000000523 sample Substances 0.000 claims description 68
- 102000040856 WT1 Human genes 0.000 claims description 22
- 108700020467 WT1 Proteins 0.000 claims description 22
- 238000006243 chemical reaction Methods 0.000 claims description 22
- 239000013558 reference substance Substances 0.000 claims description 16
- 239000013612 plasmid Substances 0.000 claims description 15
- 230000003321 amplification Effects 0.000 claims description 14
- 238000003199 nucleic acid amplification method Methods 0.000 claims description 14
- 230000000694 effects Effects 0.000 claims description 13
- 239000002773 nucleotide Substances 0.000 claims description 13
- 125000003729 nucleotide group Chemical group 0.000 claims description 13
- 239000013642 negative control Substances 0.000 claims description 10
- 239000003153 chemical reaction reagent Substances 0.000 claims description 9
- 238000002156 mixing Methods 0.000 claims description 9
- 239000013641 positive control Substances 0.000 claims description 9
- 230000008569 process Effects 0.000 claims description 8
- ABZLKHKQJHEPAX-UHFFFAOYSA-N tetramethylrhodamine Chemical compound C=12C=CC(N(C)C)=CC2=[O+]C2=CC(N(C)C)=CC=C2C=1C1=CC=CC=C1C([O-])=O ABZLKHKQJHEPAX-UHFFFAOYSA-N 0.000 claims description 8
- 238000011144 upstream manufacturing Methods 0.000 claims description 8
- 239000012295 chemical reaction liquid Substances 0.000 claims description 6
- 238000012408 PCR amplification Methods 0.000 claims description 5
- 108020004707 nucleic acids Proteins 0.000 claims description 4
- 102000039446 nucleic acids Human genes 0.000 claims description 4
- 150000007523 nucleic acids Chemical class 0.000 claims description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 4
- 239000007788 liquid Substances 0.000 claims description 2
- 239000006166 lysate Substances 0.000 claims description 2
- 238000005070 sampling Methods 0.000 claims description 2
- 238000001514 detection method Methods 0.000 abstract description 38
- 101150084041 WT1 gene Proteins 0.000 abstract description 37
- 208000032839 leukemia Diseases 0.000 abstract description 22
- 238000010839 reverse transcription Methods 0.000 abstract description 11
- 108091032973 (ribonucleotides)n+m Proteins 0.000 abstract description 10
- 238000003753 real-time PCR Methods 0.000 abstract description 8
- 239000002299 complementary DNA Substances 0.000 abstract description 7
- 108020004999 messenger RNA Proteins 0.000 abstract description 4
- 238000003759 clinical diagnosis Methods 0.000 abstract description 2
- 229940079593 drug Drugs 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 238000003752 polymerase chain reaction Methods 0.000 description 37
- 239000000243 solution Substances 0.000 description 23
- 108020004414 DNA Proteins 0.000 description 22
- 230000014509 gene expression Effects 0.000 description 14
- 210000004027 cell Anatomy 0.000 description 13
- 239000000047 product Substances 0.000 description 11
- 208000007660 Residual Neoplasm Diseases 0.000 description 9
- 238000005516 engineering process Methods 0.000 description 8
- 238000002360 preparation method Methods 0.000 description 5
- 238000003908 quality control method Methods 0.000 description 5
- 230000035945 sensitivity Effects 0.000 description 5
- 239000006228 supernatant Substances 0.000 description 5
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
- 210000001185 bone marrow Anatomy 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 238000000684 flow cytometry Methods 0.000 description 4
- 239000000203 mixture Substances 0.000 description 4
- 208000031261 Acute myeloid leukaemia Diseases 0.000 description 3
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 description 3
- 206010028980 Neoplasm Diseases 0.000 description 3
- 238000011530 RNeasy Mini Kit Methods 0.000 description 3
- 201000011510 cancer Diseases 0.000 description 3
- 238000011002 quantification Methods 0.000 description 3
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 description 2
- 208000014697 Acute lymphocytic leukaemia Diseases 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 description 2
- DRTQHJPVMGBUCF-XVFCMESISA-N Uridine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-XVFCMESISA-N 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 230000010100 anticoagulation Effects 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 238000010322 bone marrow transplantation Methods 0.000 description 2
- 238000002512 chemotherapy Methods 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- 230000007547 defect Effects 0.000 description 2
- ZMMJGEGLRURXTF-UHFFFAOYSA-N ethidium bromide Chemical compound [Br-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CC)=C1C1=CC=CC=C1 ZMMJGEGLRURXTF-UHFFFAOYSA-N 0.000 description 2
- 229960005542 ethidium bromide Drugs 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 2
- 239000007850 fluorescent dye Substances 0.000 description 2
- 210000003958 hematopoietic stem cell Anatomy 0.000 description 2
- 210000000777 hematopoietic system Anatomy 0.000 description 2
- 230000003902 lesion Effects 0.000 description 2
- 210000001165 lymph node Anatomy 0.000 description 2
- 238000012544 monitoring process Methods 0.000 description 2
- 238000004393 prognosis Methods 0.000 description 2
- 230000002441 reversible effect Effects 0.000 description 2
- 210000000952 spleen Anatomy 0.000 description 2
- 238000010186 staining Methods 0.000 description 2
- 239000011550 stock solution Substances 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 230000005945 translocation Effects 0.000 description 2
- 206010000830 Acute leukaemia Diseases 0.000 description 1
- 208000002109 Argyria Diseases 0.000 description 1
- 208000031404 Chromosome Aberrations Diseases 0.000 description 1
- 108020004635 Complementary DNA Proteins 0.000 description 1
- 102000053602 DNA Human genes 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical group OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 208000032843 Hemorrhage Diseases 0.000 description 1
- 108091028043 Nucleic acid sequence Proteins 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 238000002123 RNA extraction Methods 0.000 description 1
- 238000011529 RT qPCR Methods 0.000 description 1
- 108020004682 Single-Stranded DNA Proteins 0.000 description 1
- 108700025700 Wilms Tumor Genes Proteins 0.000 description 1
- 208000008383 Wilms tumor Diseases 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 238000000246 agarose gel electrophoresis Methods 0.000 description 1
- 208000007502 anemia Diseases 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 229940127219 anticoagulant drug Drugs 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- DRTQHJPVMGBUCF-PSQAKQOGSA-N beta-L-uridine Natural products O[C@H]1[C@@H](O)[C@H](CO)O[C@@H]1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-PSQAKQOGSA-N 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000000601 blood cell Anatomy 0.000 description 1
- 238000010804 cDNA synthesis Methods 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000024245 cell differentiation Effects 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 210000000349 chromosome Anatomy 0.000 description 1
- 231100000005 chromosome aberration Toxicity 0.000 description 1
- 229940121657 clinical drug Drugs 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 230000002559 cytogenic effect Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 230000013020 embryo development Effects 0.000 description 1
- 210000004696 endometrium Anatomy 0.000 description 1
- 238000001952 enzyme assay Methods 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 238000001502 gel electrophoresis Methods 0.000 description 1
- 230000003394 haemopoietic effect Effects 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 238000007901 in situ hybridization Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 210000005087 mononuclear cell Anatomy 0.000 description 1
- 201000008026 nephroblastoma Diseases 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 210000001672 ovary Anatomy 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 210000004976 peripheral blood cell Anatomy 0.000 description 1
- 238000002264 polyacrylamide gel electrophoresis Methods 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 239000013074 reference sample Substances 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- ZNCPFRVNHGOPAG-UHFFFAOYSA-L sodium oxalate Chemical compound [Na+].[Na+].[O-]C(=O)C([O-])=O ZNCPFRVNHGOPAG-UHFFFAOYSA-L 0.000 description 1
- 229940039790 sodium oxalate Drugs 0.000 description 1
- 238000011895 specific detection Methods 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 210000001550 testis Anatomy 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- DRTQHJPVMGBUCF-UHFFFAOYSA-N uracil arabinoside Natural products OC1C(O)C(CO)OC1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-UHFFFAOYSA-N 0.000 description 1
- 229940045145 uridine Drugs 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6844—Nucleic acid amplification reactions
- C12Q1/6851—Quantitative amplification
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/118—Prognosis of disease development
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/166—Oligonucleotides used as internal standards, controls or normalisation probes
Landscapes
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Immunology (AREA)
- Analytical Chemistry (AREA)
- Genetics & Genomics (AREA)
- Physics & Mathematics (AREA)
- Pathology (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Molecular Biology (AREA)
- General Health & Medical Sciences (AREA)
- General Engineering & Computer Science (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Oncology (AREA)
- Hospice & Palliative Care (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
The application relates to the field of fusion gene detection, in particular to a kit for detecting a human WT1 fusion gene. The kit adopts one-step reverse transcription, namely, a specific primer and an enzyme are adopted to perform reverse transcription on mRNA in a sample to form cDNA, the reverse-transcribed cDNA directly enters downstream fluorescent quantitative PCR to perform quantitative detection on the RNA of the WT1 gene in a clinical peripheral blood specimen, so that the clinical diagnosis of leukemia is assisted and the selection of related leukemia patients on clinical medicines is guided, and the kit has the technical advantages of high specificity, high accuracy and minimum detection amount.
Description
Technical Field
the application relates to the field of fusion gene detection, in particular to a kit for detecting a human WT1 fusion gene and a using method thereof.
Background
Leukemia is a malignant tumor of the hematopoietic system, and is characterized in that one or more blood cells in the hematopoietic system such as bone marrow and lymph nodes are malignant proliferated and infiltrate into various tissues and organs in the body, resulting in suppression of normal hematopoietic tissue cells and various symptoms. Leukemia is characterized clinically by fever, hemorrhage, anemia, enlargement of the liver, spleen and lymph nodes.
Recent clinical studies have shown that about 50% of leukemias have certain chromosomal aberrations, such as translocations, deletions, insertions, and the like. Related fusion genes are formed under most conditions when chromosome translocation is distorted, and the detection and monitoring of the fusion genes are beneficial to determining a treatment scheme and monitoring leukemia minimal residual lesions. However, about 50% of leukemias have no specific fusion gene, so the use of WT1 gene as a broad-spectrum marker for the detection of minimal residual lesions in leukemias is being accepted by more and more scholars. The WT1 gene is highly expressed in various leukemia cells, and the expression is increased along with the progress of the disease, thereby having the prompting and early warning functions on the prognosis and relapse of leukemia.
the WT1 gene (Wilms tumor gene) is a tumor gene isolated from Wilms tumor cells. The gene is mainly expressed during embryogenesis. In adults only a small amount of kidney, ovary, endometrium, testis, spleen and normal hematopoietic progenitor cells are expressed. The gene has time-phased expression in the blood system, and plays an important role in early hematopoietic cell differentiation.
The WT1 gene is highly expressed in bone marrow/peripheral blood of patients with primary acute leukemia, slightly expressed in normal bone marrow, and extremely low expressed in normal peripheral blood, even undetectable. The WT1 gene is found to be expressed at a high level in most acute myeloid leukemia subtypes, and about 70.0% of acute myeloid leukemia patients have high expression of WT 1-mRNA. In chronic granulosa patients, the expression level of WT1 gene gradually increases as the disease progresses from the chronic stage to the acute stage. Foreign scholars report that the positive rate of WT1 gene expression in acute lymphocytic leukemia is 47.0% -80.0%, and find that the expression of WT1 gene in acute lymphocytic leukemia is lower than that in acute myelocytic leukemia.
At present, the WT1 gene is considered to be closely related to the course of leukemia, wherein (1) the WT1 gene is highly expressed before treatment, the WT1 gene is turned negative after induction chemotherapy, and the WT1 gene expression is also increased although the original cells are less than 5% when the treatment is stopped, (2) the remission period of the WT1 gene is shorter and the patient is relapsed immediately, (3) the WT1 gene level of the patient is very low or undetectable after continuous complete remission, (4) the WT1 gene is rapidly increased after continuous high level or normal reduction, and the increase of the WT 10 -2 is more than 10, which indicates that the patient is likely to relapse, and (5) the patient is not likely to relapse after continuous low level expression.
The WT1 gene has high expression in various leukemia, the method for detecting residual leukemia by measuring WT1 gene can be used for almost all leukemia types, the quantitative detection of WT1 gene expression can evaluate the curative effect of chemotherapy or bone marrow transplantation and determine the residual quantity of leukemia cells, and has important clinical significance for early prediction of relapse and prognosis judgment.
Residual disease of leukemia (MRD), which means that a small amount of leukemia cells remain in vivo after a leukemia patient has been induced to achieve complete remission (including after bone marrow transplantation), can be detected by a more sensitive method.
The current methods for detecting MRD are diverse, and have morphology, cell culture, monoclonal antibody, metabolic enzyme assay, cytogenetics, molecular biology and the like, which are all different in accuracy, sensitivity and specificity. Recently developed faster and more applied are molecular biology methods: fluorescence In Situ Hybridization (FISH), Flow Cytometry (FCM), and Polymerase Chain Reaction (PCR) are all important in the detection of MRD.
(1) The FISH has the basic principle that single-stranded DNA (specific probe) for marking fluorescein is hybridized with the complementary DNA (specimen), and the condition of corresponding specific genes of the specimen is reflected through the quantity and the position of fluorescent signals, has accurate quantification, visual image and strong specificity, but has the highest sensitivity of 10 -2 -10 -3, can not meet the requirement of clinic on the MRD detection level, and is limited in application.
(2) FCM, using monoclonal antibody marked with fluorescein to detect the expression percentage and fluorescence intensity of different surface differentiation antigens of all cells in the specimen, expressing no or low expression on normal marrow or peripheral blood cells and expressing or high expression immunophenotype on leukemia cells to quantify MRD, FCM has wide application range, low price, large information amount, easy direct and accurate quantification, but its stable sensitivity is 10 -4, however, the related research shows that whether the residual leukemia cells can be reduced to less than 10 -4 after treatment has important meaning to the long-term remission of diseases.
(3) PCR the basic principle of PCR detection of MRD is that the target molecule mark is used as the target molecule, the target molecule is amplified by million times through polymerase chain reaction under the action of primer, and then the gel electrophoresis shows that the PCR sensitivity is 10 -5 -10 -6, the occurrence of real-time quantitative PCR well solves the problem that the common PCR is not easy to be directly and accurately quantified, the detection specificity is improved, false positive and false negative are reduced, and the PCR detection method is an important index for evaluating the MRD detection method.
in view of the above, the present application provides a kit for detecting human WT1 fusion gene by using fluorescent quantitative PCR technology.
Disclosure of Invention
The invention of the present application aims to provide a kit for detecting the human WT1 fusion gene.
in order to accomplish the purpose of the application, the technical scheme is as follows:
the application provides a kit for detecting a human WT1 fusion gene, which comprises a nucleic acid amplification reagent, wherein the nucleic acid amplification reagent comprises WT1PCR reaction liquid, internal reference PCR reaction liquid and mixed enzyme liquid;
The WT1PCR reaction solution contains a primer and a probe for detecting a WT1 fusion gene, the internal reference PCR reaction solution contains a primer and a probe for detecting an internal reference gene, and the mixed enzyme solution contains Taq enzyme, UNG enzyme, RT enzyme and Rnasin;
The primer and the probe for detecting the WT1 fusion gene comprise an upstream primer shown by SEQ ID NO. 1, a downstream primer shown by SEQ ID NO. 2 and a probe shown by SEQ ID NO. 3, wherein two ends of the probe are marked with fluorescent groups;
The internal reference PCR reaction solution is used for controlling the detection effectiveness, the primers and the probes for detecting the internal reference gene comprise an upstream primer shown by SEQ ID NO. 4, a downstream primer shown by SEQ ID NO. 5 and a probe shown by SEQ ID NO. 6, and fluorescent groups are marked at two ends of the probe.
optionally, FAM is marked at the 5 'end and TAMRA is marked at the 3' end of the nucleotide sequence shown in SEQ ID NO. 3, FAM is marked at the 5 'end and TAMRA is marked at the 3' end of the nucleotide sequence shown in SEQ ID NO. 6.
optionally, the kit further comprises a control substance, the control substance comprises a negative control and a positive control, the negative control is process water, and the positive control contains a K562 cell strain lysate.
optionally, the kit further comprises a reference substance, wherein the reference substance is used for quantifying a target gene and an internal reference gene, and the reference substance comprises the components shown in table 1:
TABLE 1
Components | The main components in the components |
WT1 reference 1: 1X 106copies | WT1 plasmid DNA |
WT1 reference 2: 1X 105copies | WT1 plasmid DNA |
WT1 reference 3: 1X 104copies | WT1 plasmid DNA |
WT1 reference 4: 1X 103copies | WT1 plasmid DNA |
Internal reference product 1: 1X 106copies | Internal reference plasmid DNA |
Internal reference 2: 1X 105copies | Internal reference plasmid DNA |
Internal reference product 3: 1X 104copies | internal reference plasmid DNA |
Internal reference 4: 1X 103copies | Internal reference plasmid DNA |
Wherein, the nucleotide sequence of the WT1 plasmid DNA is shown as SEQ ID NO. 7, and the nucleotide sequence of the internal reference plasmid DNA is shown as SEQ ID NO. 8.
Optionally, the sample to which the kit is applied is selected from a peripheral blood sample.
Optionally, the mixed enzyme solution contains 0.6-0.9 volume part of Taq enzyme, 0.1-0.3 volume part of UNG enzyme, 0.25-0.45 volume part of RT enzyme and 0.2-0.3 volume part of Rnasin; the control enzyme solution contains 0.6-0.9 volume part of Taq enzyme and 0.1-0.3 volume part of UNG enzyme;
preferably, the mixed enzyme solution contains 0.8 volume part of Taq enzyme, 0.2 volume part of UNG enzyme, 0.375 volume part of RT enzyme and 0.25 volume part of Rnasin; the control enzyme solution contains 0.8 volume part of Taq enzyme and 0.2 volume part of UNG enzyme;
Wherein the unit of activity of UNG enzyme is 1U/. mu.l, the unit of activity of Taq enzyme is 5U/. mu.l, and the unit of activity of RT enzyme is 200U/. mu.l.
the application also relates to a primer and a probe for detecting the fusion gene of the human WT1, wherein the primer and the probe for detecting the fusion gene of the WT1 comprise an upstream primer shown by SEQ ID NO. 1, a downstream primer shown by SEQ ID NO. 2 and a probe shown by SEQ ID NO. 3, and two ends of the probe are marked with fluorescent groups;
preferably, the kit also comprises a primer and a probe for detecting the reference gene, wherein the primer and the probe for detecting the reference gene comprise an upstream primer shown by SEQ ID NO. 4, a downstream primer shown by SEQ ID NO. 5 and a probe shown by SEQ ID NO. 6, and fluorescent groups are marked at two ends of the probe.
Optionally, the 5 'end of the nucleotide sequence shown in SEQ ID NO. 3 is marked with FAM, and the 3' end is marked with TAMRA; the 5 'end of the nucleotide sequence shown in SEQ ID NO. 6 is marked with FAM, and the 3' end is marked with TAMRA.
The application also relates to a method for using the kit, which at least comprises the following steps:
(1) Sample treatment: extracting RNA to obtain a sample;
(2) Preparing an amplification reagent: mixing the WT1PCR reaction solution with the mixed enzyme solution to obtain a WT1PCR premix; mixing the internal reference PCR reaction solution with the mixed enzyme solution to obtain an internal reference PCR premix;
(3) Sample adding: respectively sampling from a sample, a negative control, a positive control, WT1 reference products 1-WT 1 reference products 4 and internal reference products 1-4, respectively adding into each PCR premix and each internal reference PCR premix,
(4) PCR amplification;
(5) And (6) detecting.
The technical scheme of the application has at least the following beneficial effects:
the kit adopts a reverse transcription-fluorescent quantitative PCR (RT-RQ-PCR) technology, namely mRNA in a sample is subjected to reverse transcription before the fluorescent quantitative PCR is carried out, a template of the fluorescent quantitative PCR is cDNA instead of genomic DNA, and a two-step reverse transcription method and a one-step reverse transcription method are commonly used. The kit adopts one-step reverse transcription, namely, mRNA in a sample is reversely transcribed into cDNA by adopting a specific primer and an enzyme, and the cDNA after reverse transcription directly enters downstream fluorescent quantitative PCR. The kit adopts PCR combined with real-time fluorescent probe technology to carry out quantitative detection on the RNA of WT1 gene in a clinical peripheral blood specimen, thereby assisting the clinical diagnosis of leukemia and guiding the selection of related leukemia patients to clinical drugs. Has the technical advantages of high specificity, high accuracy and minimum detection amount:
1. The kit has the advantages of high minimum detection quantity, sensitivity of 10 2 copies, wide linear range and capability of carrying out quantification in the range of 10 2 -10 10 copies.
2. The kit has strong specificity: the fluorescent probe and the template are hybridized, and the change of a fluorescent signal in the PCR amplification process is directly detected through a photoelectric conduction system to obtain a quantitative result, so that the specificity is greatly improved compared with the traditional PCR technology.
3. the kit has good stability, because the threshold value is set in the exponential amplification stage, the concentration of each reaction component is relatively stable, and the C T value and the logarithm of a fluorescence signal form a linear relation.
4. The reagent kit has little pollution: generally, PCR products need to be observed through agarose gel electrophoresis, ethidium bromide staining and ultraviolet light, or detected through polyacrylamide gel electrophoresis and silver staining, not only various instruments are needed, but also time and labor are wasted, and a staining agent ethidium bromide is harmful to human bodies, and the complicated experimental processes provide opportunities for pollution and false positive. The kit adopts one-step reverse transcription, only a cover needs to be opened once during sample adding, the subsequent process is completely closed tube operation, and the treatment after reverse transcription or PCR is not needed, so the operation is simple and convenient, the time is saved, the pollution is reduced, and a plurality of defects in the conventional PCR operation are avoided.
The present application is further illustrated with reference to specific examples. It should be understood that these examples are for illustrative purposes only and are not intended to limit the scope of the present application.
Detailed Description
The kit of the embodiment combines the fluorescent quantitative PCR technology and the reverse transcription technology, namely RT-RQ-PCR technology, and the expression level of the WT1 fusion gene in a sample is detected by a one-step method by applying the fluorescent quantitative PCR technology while reverse transcribing mRNA in the sample into cDNA. The kit provided by the embodiment of the application only needs to open the cover once during sample adding, the subsequent process is completely closed tube operation, and reverse transcription or PCR post-treatment is not needed, so that the operation is simple and convenient, the time is saved, the pollution is reduced, a plurality of defects in conventional PCR operation are avoided, and the kit has the technical advantages of high specificity, high accuracy and minimum detection amount.
Meanwhile, the kit of the embodiment of the present application also uses a uridine enzyme (UNG) antipollution system, which selectively degrades U-DNA by heating, to prevent contamination of the previous PCR amplification product; and the effectiveness of the whole kit detection process is controlled by adopting an internal reference gene.
In addition, the kit of the embodiment of the application also adopts two sets of reference substance standard curves to respectively quantify the target gene and the reference gene so as to achieve an accurate ratio.
Specifically, the kit of the embodiment of the present application is specifically shown in table 2:
TABLE 2
Wherein the mixed enzyme solution contains 0.6-0.9 volume part of Taq enzyme, 0.1-0.3 volume part of UNG enzyme, 0.25-0.45 volume part of RT enzyme and 0.2-0.3 volume part of Rnasin; preferably 0.8 volume part of Taq enzyme, 0.2 volume part of UNG enzyme, 0.375 volume part of RT enzyme and 0.25 volume part of Rnasin;
The reference enzyme solution contains 0.6-0.9 volume part of Taq enzyme and 0.1-0.3 volume part of UNG enzyme; preferably, the control enzyme solution contains 0.8 volume part of Taq enzyme and 0.2 volume part of UNG enzyme;
Wherein the unit of activity of UNG enzyme is 1U/. mu.l, the unit of activity of Taq enzyme is 5U/. mu.l, and the unit of activity of RT enzyme is 200U/. mu.l.
specifically, the nucleotide sequences of the primers and probes are specifically shown in table 3:
table 3:
specifically, the nucleotide sequence of the plasmid DNA is specifically shown in table 4:
TABLE 4
The sample requirements of the kit of the present application are:
Collecting samples: the kit is suitable for anticoagulation peripheral blood samples. The anticoagulation sample requirement is as follows: the anticoagulant is EDTA, sodium oxalate or sodium citrate.
Sample preservation: uniformly mixing an anticoagulated peripheral blood sample with Trizol in a ratio of 1:3, or enriching nucleated cells of broken red blood cells of a fresh sample, suspending, adding Trizol by 3 times of volume, uniformly mixing, and storing for no more than 24 hours at 4 ℃. Stored at-20 ℃ for a long time.
Sample transportation: storing in Trizol anticoagulated peripheral blood sample at 4 deg.C, and transporting at low temperature.
RNA extraction requires: extraction was performed using the Rneasy Mini kit. Or extracting by using a Trizol method. The extracted RNA is recommended to be detected immediately, otherwise, the RNA is required to be stored below 20 ℃ in a short time and at 80 ℃ in a long time, so that the RNA degradation is prevented.
Fresh peripheral blood samples were recommended for naive patients. The mononuclear cells obtained by separating the sample by lymphocyte separating medium are recommended for the patient with Minimal Residual Disease (MRD). According to the definition of the minimum residual focus (namely, the number of cancer cells in 1 ten thousand cells is detected, and if the number is less than 1, the cancer cells are judged to be negative), therefore, for a patient after treatment, in order to detect whether the minimum residual focus exists in a bone marrow specimen, more than 1ug of total RNA is recommended to be taken for an experiment, the stock solution is subjected to WT1 fusion gene detection, and after the RNA stock solution is diluted by 100 times, internal reference gene detection is carried out so as to ensure that the concentration of the corresponding detection gene is in a linear range.
the application method of the kit comprises the following steps:
1. Sample treatment (Note: 200. mu.l each of negative control and positive control was treated with the specimen):
RNA nucleic acid was extracted using Rneasy Mini kit, 400. mu.l of the specimen stored in Trizol was taken, 400. mu.l of chloroform was added thereto, and the mixture was mixed well and allowed to stand at room temperature for 5 minutes. Centrifuging at 15000rpm for 10 min, sucking colorless supernatant after centrifugation, adding equal volume of buffer RLT, and mixing uniformly, wherein the rest steps are described in the Rneasy Mini kit instruction.
Or extracting RNA by using a Trizol method, which comprises the following specific steps:
400 μ l of the specimen stored in Trizol was taken, 400 μ l of chloroform was added thereto, and the mixture was mixed well and allowed to stand at room temperature for 5 minutes. Centrifuged at 15000rpm for 10 minutes and the colorless supernatant was aspirated.
② adding equal volume of precooled isopropanol into the supernatant, reversing and mixing evenly, and then placing for 10 minutes at room temperature. Centrifuge at 15000rpm for 10 minutes and discard the supernatant.
③ to the centrifuge tube, 300. mu.l of precooled 70% ethanol was added, centrifuged at 15000rpm for 5 minutes, and the supernatant was discarded. The ethanol was evaporated at room temperature for 10 minutes.
200. mu.l DEPC-ddH 2 O was added and dissolved to serve as a template for the relevant PCR reaction.
2. Preparation of amplification reagents:
And taking the WT1PCR reaction solution, the internal reference PCR reaction solution, the mixed enzyme solution, the positive control and the reference substance out of the kit, melting at room temperature, shaking and mixing uniformly, and centrifuging at 2000rpm for 10 s.
the reaction system is prepared as follows: WT1PCR reaction solution 8. mu.l + mixed enzyme solution 2. mu.l or reference gene PCR reaction solution 8. mu.l + mixed enzyme solution 2. mu.l (note that the number of tubes should be the sum of the sample number, 2-tube reference, 4-tube reference).
the prepared PCR premix is respectively subpackaged into each PCR tube according to the amount of 10 mu l per tube.
3. sample adding: mu.l of each of the control, reference and sample treatment solutions was added to a centrifuge tube containing the PCR premix, and the tube was closed and transferred to the detection zone.
PCR amplification:
4.1 amplification conditions
ABI series fluorescent PCR detector, Bio-Rad CFX96 fluorescent PCR detector amplification conditions: 30min at 42 ℃; 94 ℃ for 5 min; (94 ℃, 15 sec; 60 ℃, 60sec)40 cycles. The reaction system was 25. mu.l. The fluorescent signal was collected at 60 ℃ in the second step of the PCR cycle.
Stratagene Mx3000p fluorescent PCR detector amplification conditions: 30min at 42 ℃; 94 ℃ for 5 min; (94 ℃, 45 sec; 60 ℃, 80sec)40 cycles. The reaction system was 25. mu.l. The fluorescent signal was collected at 60 ℃ in the second step of the PCR cycle.
4.2 detection channel and reference fluorescence
the detection channels of the ABI 7300 fluorescent PCR detector and the ABI 7500 fluorescent PCR detector are as follows: FAM-TAMRA, reference fluorescence was set to none.
the detection channel of the Bio-Rad CFX96 fluorescent PCR detector is as follows: FAM.
The detection channels of the Stratagene Mx3000p fluorescent PCR detector are: FAM. The reference fluorescence was set to none.
5. And (3) detection:
(1) Determination of the baseline: the software defaults to baseline the mean fluorescence signal for 3-15 cycles. In the experiment, the section with smaller curve fluctuation and more stability is generally selected as the baseline, and the user can adjust the curve according to the actual situation. The starting point is to avoid the signal increase due to high temperature for the first few cycles, where the signal has dropped to background level and is stable, and the ending point is to avoid covering where the signal has started to increase significantly. According to different trends of the experimental curve, the general start value can be selected to be between 3 and 12; the stop value is selected on the basis that the interval between the starting point and the end point can be more than 8 cycles preferably so as to better meet the mathematical requirement of statistical baseline standard deviation.
(2) determination of the threshold: in the case of no amplification of the negative control, the threshold is set at the highest point of the sample without amplification curve, i.e. higher than the highest point of the growth curve without amplification (i.e. no point appears in the column "Component" of the result analysis), and the initial threshold is determined on the basis that no negative control is detected.
(3) note that: for the same sample, the analysis of the standard curves of negative and positive controls and reference substances needs to be carried out at the same time, and the reaction liquid of the target gene and the internal reference gene needs to be analyzed by using the same baseline and threshold value.
the present application is further illustrated by the following specific examples, which are all commercially available materials unless otherwise specified.
Example 1
a kit for detecting a human WT1 fusion gene, which comprises the following components shown in Table 5:
Table 5:
Wherein the unit of activity of UNG enzyme is 1U/. mu.l, the unit of activity of Taq enzyme is 5U/. mu.l, and the unit of activity of RT enzyme is 200U/. mu.l.
the packaging and contents of the components of the kit are shown in table 6:
Table 6:
Example 2: linear detection
Selecting 100 ul of WT1 plasmid and plasmid of internal reference gene with determined concentration, preparing high concentration DNA sample (L0), using the two samples as sample linear quality control L0 of the kit of example 1, then adding process water at 1: the L0 samples were serially diluted with 10 gradients to give two sets of linear quality controls L1, L2, L3 and L4, respectively. The specific compositions are shown in tables 9 and 10.
And (3) performing linear fitting by taking the logarithmic value of the concentration as Y and the CT mean value as X, and calculating the linear correlation coefficient r of the linear fitting. The specific experimental results are shown in tables 7 and 8:
TABLE 7
WT1 linear quality control article | Number of entry reaction templates (copies) |
WT1-L0 | 5×106 |
WT1-L1 | 5×105 |
WT1-L2 | 5×104 |
WT1-L3 | 5000 |
WT1-L4 | 500 |
r value | ≥0.980 |
TABLE 8
Internal reference gene linear quality control product | Number of entry reaction templates (copies) |
Internal reference of formula-L0 | 5×106 |
Internal reference of formula-L1 | 5×105 |
Internal reference of formula-L2 | 5×104 |
ABL-L3 | 5000 |
internal reference of formula-L4 | 500 |
r value | ≥0.980 |
The operation is carried out according to the detection method of the kit in the embodiment 1, the logarithmic value of the concentration of the reference substance is Y, the CT mean value is X, the linear fitting is carried out, the linear correlation coefficient r is calculated, and the r value is more than or equal to 0.980.
Example 3: accuracy detection of the kit of the present application
the kit of example 1 was used to test for accuracy references: the preparation method of the accuracy reference substance is shown in table 9:
TABLE 9
The prepared accurate reference substances were tested, and the experimental results are shown in table 10:
Watch 10
by adopting the kit for detecting the accuracy reference substance, the positive coincidence rate is 100%.
Example 4: assay-specific detection of the kits of the present application
The specific reference was tested using the kit of example 1: the preparation method of the specific reference substances is shown in table 11:
TABLE 11
The prepared assay-specific reference was tested and the experimental results are shown in table 12:
TABLE 12
When the kit is used for detecting the specific reference sample, the negative coincidence rate is 100%.
example 4: precision detection of the kit of the present application
The precision reference was tested using the kit of example 1: the preparation method of the precision reference substance is shown in table 13:
Watch 13
Detecting the prepared precision reference substance; the experimental results obtained are shown in table 14:
TABLE 14
The reagent kit can detect each precision reference product by repeating the detection in corresponding reaction liquid for 10 times, and the CV value of experimental data is less than or equal to 5 percent.
Example 5: minimum detection amount detection of kit of the application
The kit of example 1 was used to test the lowest detectable reference: the formulation of the lowest detectable amount reference is shown in table 15:
watch 15
Numbering | Entering a reaction mould (copies) | volume of each mark |
WT1-LN | 100 | mu.l of the linear quality control product L4 was added to 80. mu.l of water and mixed by shaking. |
The lowest detected amount obtained by the preparation was detected, and the obtained experimental results are shown in table 16:
TABLE 16
Reference product with minimum detection amount | CTvalue of |
WT1-LN | 31.86 |
The kit is used for detecting the reference substance with the lowest detection amount, and the lowest detection amount is 100 copies/reaction.
Although the present application has been described with reference to preferred embodiments, it is not intended to limit the scope of the claims, and many possible variations and modifications may be made by one skilled in the art without departing from the spirit of the application.
Sequence listing
<110> Suzhou Yuntai biomedical science and technology Co., Ltd
<120> kit for detecting human WT1 fusion gene and method of use thereof
<160> 8
<170> SIPOSequenceListing 1.0
<210> 1
<211> 21
<212> DNA
<213> Artificial Sequence (Artificial Sequence)
<400> 1
agaatacaca cgcacggtgt c 21
<210> 2
<211> 20
<212> DNA
<213> Artificial Sequence (Artificial Sequence)
<400> 2
atgccgaccg tacaagagtc 20
<210> 3
<211> 25
<212> DNA
<213> Artificial Sequence (Artificial Sequence)
<400> 3
ctccaggcac acgtcgcaca tcctg 25
<210> 4
<211> 31
<212> DNA
<213> Artificial Sequence (Artificial Sequence)
<400> 4
tggagataac actctaagca taactaaagg t 31
<210> 5
<211> 21
<212> DNA
<213> Artificial Sequence (Artificial Sequence)
<400> 5
gatgtagttg cttgggaccc a 21
<210> 6
<211> 28
<212> DNA
<213> Artificial Sequence (Artificial Sequence)
<400> 6
ccatttttgg tttgggcttc acaccatt 28
<210> 7
<211> 501
<212> DNA
<213> Artificial Sequence (Artificial Sequence)
<400> 7
tttctctatt ccattgcctt tccacagtaa cttatacctg tttgaaccat ttcaaaggtg 60
cttagaactt atgaagagag tacagtttta gaagaaaggg caaagctctc tgtgacatta 120
gaacgctttc ctccttcccc tagttgagtt gctgctggga gctccagctc agtgaaatgg 180
acagaagggc agagcaacca cagcacaggg tacgagagcg ataaccacac aacgcccatc 240
ctctgcggag cccaatacag aatacacacg cacggtgtct tcagaggcat tcaggatgtg 300
cggcgtgtgc ctggagtagc cccgactctt gtacggtcgg catctgagac cagtgagaaa 360
cgccccttca tgtgtgctta cccaggctgc aataagagat attttaagct gtcccactta 420
cagatgcaca gcaggaagca cactggtgag aaaccatacc agtgtgactt caaggactgt 480
gaacgaaggt tttctcgttc a 501
<210> 8
<211> 757
<212> DNA
<213> Artificial Sequence (Artificial Sequence)
<400> 8
aaaatgttgg agatctgcct gaagctggtg ggctgcaaat ccaagaaggg gctgtcctcg 60
tcctccagct gttatctgga agaagccctt cagcggccag tagcatctga ctttgagcct 120
cagggtctga gtgaagccgc tcgttggaac tccaaggaaa accttctcgc tggacccagt 180
gaaaatgacc ccaacctttt cgttgcactg tatgattttg tggccagtgg agataacact 240
ctaagcataa ctaaaggtga aaagctccgg gtcttaggct ataatcacaa tggggaatgg 300
tgtgaagccc aaaccaaaaa tggccaaggc tgggtcccaa gcaactacat cacgccagtc 360
aacagtctgg agaaacactc ctggtaccat gggcctgtgt cccgcaatgc cgctgagtat 420
ctgctgagca gcgggatcaa tggcagcttc ttggtgcgtg agagtgagag cagtcctggc 480
cagaggtcca tctcgctgag atacgaaggg agggtgtacc attacaggat caacactgct 540
tctgatggca agctctacgt ctcctccgag agccgcttca acaccctggc cgagttggtt 600
catcatcatt caacggtggc cgacgggctc atcaccacgc tccattatcc agccccaaag 660
cgcaacaagc ccactgtcta tggtgtgtcc cccaactacg acaagtggga gatggaacgc 720
acggacatca ccatgaagca caagctgggc gggggcc 757
Claims (9)
1. A kit for detecting a human WT1 fusion gene is characterized by comprising a nucleic acid amplification reagent, wherein the nucleic acid amplification reagent comprises WT1PCR reaction liquid, internal reference PCR reaction liquid and mixed enzyme liquid;
The WT1PCR reaction solution contains a primer and a probe for detecting a WT1 fusion gene, the internal reference PCR reaction solution contains a primer and a probe for detecting an internal reference gene, and the mixed enzyme solution contains Taq enzyme, UNG enzyme, RT enzyme and Rnasin;
The primer and the probe for detecting the WT1 fusion gene comprise an upstream primer shown by SEQ ID NO. 1 and a downstream primer shown by SEQ ID NO. 2 and a probe shown by SEQ ID NO. 3, wherein two ends of the probe are marked with fluorescent groups;
the primer and the probe for detecting the reference gene comprise an upstream primer shown by SEQ ID NO. 4, a downstream primer shown by SEQ ID NO. 5 and a probe shown by SEQ ID NO. 6, wherein two ends of the probe are marked with fluorescent groups.
2. The kit according to claim 1, wherein the nucleotide sequence shown in SEQ ID NO. 3 is labeled with FAM at the 5 'end and TAMRA at the 3' end, and the nucleotide sequence shown in SEQ ID NO. 6 is labeled with FAM at the 5 'end and TAMRA at the 3' end.
3. The kit according to claim 1, further comprising a control, wherein the control comprises a negative control and a positive control, the negative control is process water, and the positive control contains a K562 cell line lysate.
4. The kit according to claim 1, further comprising a reference substance for quantifying the target gene and the internal reference gene, wherein the reference substance comprises:
Wherein, the nucleotide sequence of the WT1 plasmid DNA is shown as SEQ ID NO. 7, and the nucleotide sequence of the internal reference plasmid DNA is shown as SEQ ID NO. 8.
5. The kit of claim 1, wherein the sample to which the kit is applied is selected from a peripheral blood sample.
6. The kit according to claim 1, wherein the mixed enzyme solution comprises 0.6 to 0.9 parts by volume of Taq enzyme, 0.1 to 0.3 parts by volume of UNG enzyme, 0.25 to 0.45 parts by volume of RT enzyme, and 0.2 to 0.3 parts by volume of Rnasin; the control enzyme solution contains 0.6-0.9 volume part of Taq enzyme and 0.1-0.3 volume part of UNG enzyme;
Preferably, the mixed enzyme solution contains 0.8 volume part of Taq enzyme, 0.2 volume part of UNG enzyme, 0.375 volume part of RT enzyme and 0.25 volume part of Rnasin; the control enzyme solution contains 0.8 volume part of Taq enzyme and 0.2 volume part of UNG enzyme;
Wherein the unit of activity of UNG enzyme is 1U/. mu.l, the unit of activity of Taq enzyme is 5U/. mu.l, and the unit of activity of RT enzyme is 200U/. mu.l.
7. The primer and the probe for detecting the human WT1 fusion gene are characterized in that the primer and the probe for detecting the WT1 fusion gene comprise an upstream primer shown by SEQ ID NO. 1, a downstream primer shown by SEQ ID NO. 2 and a probe shown by SEQ ID NO. 3, wherein two ends of the probe are marked with fluorescent groups;
Preferably, the kit also comprises a primer and a probe for detecting the reference gene, wherein the primer and the probe for detecting the reference gene comprise an upstream primer shown by SEQ ID NO. 4, a downstream primer shown by SEQ ID NO. 5 and a probe shown by SEQ ID NO. 6, and fluorescent groups are marked at two ends of the probe.
8. the primers and probes as claimed in claim 7, wherein the nucleotide sequence shown in SEQ ID NO. 3 is labeled with FAM at the 5 'end and TAMRA at the 3' end; the 5 'end of the nucleotide sequence shown in SEQ ID NO. 6 is marked with FAM, and the 3' end is marked with TAMRA.
9. A method of using the kit according to any one of claims 1 to 8, comprising at least the steps of:
(1) sample treatment: extracting RNA to obtain a sample;
(2) Preparing an amplification reagent:
Mixing the WT1PCR reaction solution with the mixed enzyme solution to obtain a WT1PCR premix; mixing the internal reference PCR reaction solution with the mixed enzyme solution to obtain an internal reference PCR premix;
(3) Sample adding: respectively sampling samples from a sample, a negative control, a positive control, WT1 reference products 1-WT 1 reference products 4 and internal reference products 1-4, and respectively adding the samples into each PCR premix and each internal reference PCR premix;
(4) PCR amplification;
(5) And (6) detecting.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201810549583.1A CN110551817A (en) | 2018-05-31 | 2018-05-31 | Kit for detecting human WT1 fusion gene and use method thereof |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201810549583.1A CN110551817A (en) | 2018-05-31 | 2018-05-31 | Kit for detecting human WT1 fusion gene and use method thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
CN110551817A true CN110551817A (en) | 2019-12-10 |
Family
ID=68734533
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201810549583.1A Pending CN110551817A (en) | 2018-05-31 | 2018-05-31 | Kit for detecting human WT1 fusion gene and use method thereof |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN110551817A (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN113652504A (en) * | 2020-05-12 | 2021-11-16 | 北京果壳生物科技有限公司 | Novel complete reagent and kit for coronavirus nucleic acid detection |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101781677A (en) * | 2009-01-15 | 2010-07-21 | 中山大学达安基因股份有限公司 | Kit for detecting leukemia broad-spectrum marker WT1 gene mRNA expression |
CN102827937A (en) * | 2012-09-06 | 2012-12-19 | 上海源奇生物医药科技有限公司 | Primer and probe for detecting relative fusion genes of leukemia and kit of primer and probe |
CN102912018A (en) * | 2012-09-29 | 2013-02-06 | 童永清 | Kit for detecting expression index of mRNA (messager Ribose Nucleic Acid) of WT1 (Wilms Tumor 1) gene |
CN104328209A (en) * | 2014-11-24 | 2015-02-04 | 济南市中心医院 | Primer and kit for fast detection method of leukemia minimal residual disease WT1 gene |
CN104937112A (en) * | 2013-01-22 | 2015-09-23 | 大塚制药株式会社 | Quantification method for expression level of WT1 mRNA |
-
2018
- 2018-05-31 CN CN201810549583.1A patent/CN110551817A/en active Pending
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101781677A (en) * | 2009-01-15 | 2010-07-21 | 中山大学达安基因股份有限公司 | Kit for detecting leukemia broad-spectrum marker WT1 gene mRNA expression |
CN102827937A (en) * | 2012-09-06 | 2012-12-19 | 上海源奇生物医药科技有限公司 | Primer and probe for detecting relative fusion genes of leukemia and kit of primer and probe |
CN102912018A (en) * | 2012-09-29 | 2013-02-06 | 童永清 | Kit for detecting expression index of mRNA (messager Ribose Nucleic Acid) of WT1 (Wilms Tumor 1) gene |
CN104937112A (en) * | 2013-01-22 | 2015-09-23 | 大塚制药株式会社 | Quantification method for expression level of WT1 mRNA |
CN104328209A (en) * | 2014-11-24 | 2015-02-04 | 济南市中心医院 | Primer and kit for fast detection method of leukemia minimal residual disease WT1 gene |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN113652504A (en) * | 2020-05-12 | 2021-11-16 | 北京果壳生物科技有限公司 | Novel complete reagent and kit for coronavirus nucleic acid detection |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Amabile et al. | Real-time quantification of different types of bcr-abl transcript in chronic myeloid leukemia | |
CN111909997B (en) | Application of miRNA marker in preparation of product for evaluating curative effect of olanzapine on schizophrenia treatment and kit | |
Cross et al. | Minimal residual disease after bone marrow transplant for chronic myeloid leukaemia detected by the polymerase chain reaction | |
CN113718021A (en) | Primer, probe and kit for quantitatively detecting BCR-ABL1 fusion gene | |
Luthra et al. | TaqMan RT-PCR assay coupled with capillary electrophoresis for quantification and identification of bcr-abl transcript type | |
CN103103251A (en) | Kit for detecting FLT3-ITD (Fms-like tyrosine kinase 3-internal tandem duplication) gene mutation by using fluorescence PCR (Polymerase Chain Reaction) capillary electrophoresis | |
CN109880825B (en) | Circular RNA hsa _ circ _0012152 and application thereof | |
CN110551816A (en) | kit for detecting human PML-RARa fusion gene and use method thereof | |
CN100360684C (en) | Fluorescent quantitative RT-PCR detecting kit of 2-f(o)etoprotein (AFP)mRNA | |
CN106244675B (en) | Kit for adult AML risk stratification and clinical prognosis evaluation and application of CPNE3 | |
CN110551817A (en) | Kit for detecting human WT1 fusion gene and use method thereof | |
CN110656171B (en) | Use of small nucleolus ribonucleic acid SNORD33 as biomarker for preparing detection kit | |
CN107641650B (en) | Application of NR1H 3in accurate target detection and prognosis evaluation of acute myelogenous leukemia | |
CA2851752A1 (en) | Method for quantifying renal markers by urinary dosage | |
CN110551821B (en) | Primers, probe and kit for detecting MEF2D gene rearrangement by using fluorescent quantitative PCR | |
CN112961919B (en) | Circular RNA hsa _ circ _0059706, specific amplification primer thereof and application | |
CN103725787B (en) | Fluorescent PCR (Polymerase Chain Reaction) detection kit for fusion genes of leukemia | |
CN107345244A (en) | Detect method, primer and the kit of leukaemia TEL AML1 fusions | |
CN112430648A (en) | Oligonucleotide, method and kit for detecting ETV6-RUNX1 fusion gene in sample | |
CN103740835B (en) | A kind of leukemia fusion gene fluorescence PCR detection reagent kit | |
CN110804663A (en) | Primer, kit and detection method for detecting human CYP2C19 gene mutation | |
CN103923981A (en) | HLA-B*27 allele detection method and kit thereof | |
CN104711255B (en) | THSD7A gene orders and expression change detection and its application in coronary disease disease forecasting | |
Matsushita et al. | Quantitative analysis of PRAME for detection of minimal residual disease in leukemia | |
TW201807197A (en) | Method for assisting determination of hematological stage of childhood acute lymphoblastic leukemia |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
RJ01 | Rejection of invention patent application after publication |
Application publication date: 20191210 |
|
RJ01 | Rejection of invention patent application after publication |